Resultados preliminares no auditados del cuarto trimestre y del año fiscal 4
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
ROCKVILLE, MD, January 9, 2024 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2023.
Preliminary Unaudited Fourth Quarter and Full Year 2023 Results
Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022.
· Core revenue is expected to be between $7.0 million and $7.2 million, compared to $10.6 million in the fourth quarter of 2022.
· Strategic Platform License (SPL) Program-related revenue is expected to be approximately $8.5 million, compared to $1.9 million in the fourth quarter of 2022.
Total revenue for the fiscal year of 2023 is expected to be between $41.1 and $41.3 million, compared to $44.3 million for fiscal year 2022.
· Se espera que los ingresos básicos estén entre $29.6 millones y $29.8 millones, en comparación con los $39.6 millones del año fiscal 2022.
· Se espera que los ingresos relacionados con el programa SPL sean de aproximadamente $11.4 millones, en comparación con $4.6 millones para el año fiscal 2022.
Se espera que el total de efectivo, equivalentes de efectivo e inversiones al 31 de diciembre de 2023 sea de aproximadamente $210 millones.
"MaxCyte reported preliminary revenue above our updated total revenue guidance provided in December. The operating environment in the Cell Therapy industry was challenging in 2023; however, we remain confident in the opportunity that exists for MaxCyte in the years ahead," said Maher Masoud, presidente y director ejecutivo de MaxCyte. "In 2023, we supported our partner, Vertex Pharmaceuticals Inc., in the approval of CASGEVY?, the first non-viral cell therapy product approved by the FDA. This milestone ushers in a new era of engineered cell therapies to treat diseases and validates the value of our platform. We are committed to supporting our partners in their commercial journeys and the profound impact they will make in patients' lives."
MaxCyte's fourth quarter and full year results are preliminary and unaudited and subject to change in connection with the completion of MaxCyte's quarterly and year-end closing processes and the preparation of its audited financial statements for the quarter and fiscal year ended December 31, 2023. As a result, these preliminary results may differ from the actual results that will be reflected in MaxCyte's consolidated financial statements for the quarter and fiscal year ended December 31, 2023, which are expected to be released in March 2024 and will be included in MaxCyte's Annual Report on Form 10-K.
Acerca de MaxCyte
En MaxCyte, buscamos la excelencia en la ingeniería celular para maximizar el potencial de las células para mejorar la vida de los pacientes. Hemos dedicado más de 20 años a perfeccionar nuestra experiencia creando las mejores plataformas, perfeccionando el arte del flujo de trabajo de transfección y aventurándonos más allá de los procesos actuales para innovar en las soluciones del mañana. ¿Nuestro EXPERTO? La plataforma, que se basa en nuestra tecnología Flow Electroporation®, ha sido diseñada para respaldar el mercado de terapia celular en rápida expansión y puede utilizarse en todo el sector de terapia celular de alto crecimiento, desde el descubrimiento y el desarrollo hasta la comercialización de la próxima generación. medicamentos basados en células. La familia de productos ExPERT incluye: cuatro instrumentos, ¿ATx?, STx?, GTx? y VLx?; una cartera de conjuntos o desechables de procesamiento relacionados con propiedad exclusiva; y protocolos de software, todos respaldados por una sólida cartera de propiedad intelectual a nivel mundial. By Al brindarles a nuestros socios la plataforma tecnológica adecuada, así como apoyo científico, técnico y regulatorio, nuestro objetivo es guiarlos en su viaje para transformar la salud humana. Conoce más en maxcyte.com y síguenos en Twitter y Etiqueta LinkedIn.
Declaraciones a futuro
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements con respecto a the leadership transition and statements regarding expected core business revenue and SPL Program-related revenue for the year ending December 31, 2023. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "prospect," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements about the Company's preliminary results of operations, including fourth quarter and full year 2023 total revenue, core revenue, and SPL program revenue and statements about possible or assumed future results of operations or financial position. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with the management transition, the timing and outcome of our customers' ongoing and planned clinical trials; the adequacy of our cash resources and availability of financing on commercially reasonable terms; general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners; and market acceptance and demand for our technology and products. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 15, 2023, as well as in discussions of potential risks, uncertainties, and other important factors in our most recent Quarterly report on Form 10-Q and the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under "SEC Filings" on the Investors page of our website at http://investors.maxcyte.com. Todas las declaraciones prospectivas representan nuestros puntos de vista solo a la fecha de este comunicado de prensa y no se debe confiar en que representen nuestros puntos de vista a cualquier fecha posterior. Renunciamos explícitamente a cualquier obligación de actualizar cualquier declaración prospectiva, ya sea como resultado de nueva información, eventos futuros u otros. No se realizan representaciones ni garantías (expresas o implícitas) sobre la precisión de dichas declaraciones prospectivas.
Contactos de MaxCyte:
Asesor de IR de EE. UU. Grupo Gilmartin David Deuchler | +1 415-937-5400
| |
Relaciones con los medios de EE. UU. Sísmico Valeria Enes
Consejero Designado y Sociedad Conjunta Broker panmure gordon Emma Earl/Freddy Crossley Corretaje corporativo Rupert Dearden
| +1 408-497-8568
44 0 20 7886 2500 | |
Asesor de RI del Reino Unido Consejo ICR Mary Jane Elliott chris galés
|
44 0 203 709 5700
| |
|
| |
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.